A clinical trial of a study medicine for people with advanced ovarian cancer
The C4161001 study is researching whether a study medicine is safe and effective in the treatment of advanced ovarian cancer.
Unfortunately, current treatment options are limited and may not work for everyone. Doctors are working to find better treatment options for people living with advanced ovarian cancer.
Who may participate
Joining a clinical trial is an important and personal decision. Your doctor may have mentioned the C4161001 study to you, or perhaps you found your way here by yourself. Either way, thank you for your interest.
This study may be an option if you:
- Are 18 years and older
- Have been diagnosed with advanced ovarian cancer
- Have received at least 1 anti-cancer therapy
There are other requirements to participate in this study. The study doctor will explain these to you.
Condition
Ovarian cancer
Age
18 years or older
Sex
Male or Female
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.
What to expect
If you decide to participate in this study, you will take the study medicine by mouth twice a day, in 28-day cycles. You will continue to receive the study medicine for as long as it is benefiting you.
You will need to attend regular visits so the study team can monitor how you are responding to the study medicine. These visits will include health assessments, tests and scans.
Length of study treatment
6 months or longer
Number of study visits
At least 12 visits
Long-term follow up
Phone calls to check in every 2 months
About ovarian cancer
Ovarian cancer is a group of diseases that originates in a women’s ovaries, or in the related areas of the fallopian tubes and the peritoneum (the tissue lining that covers organs in the abdomen). Ovarian cancers come in a variety of different tumor types. The most common tumor type is high-grade serous carcinoma, accounting for about 70% of ovarian cancer cases.
Frequently asked questions
Time in the study will vary for everyone and depends on how your cancer responds to the study medicine. You may continue to receive the study medicine for as long as it is benefiting you. After completing the course of study medicine, you will need to continue with long term follow-up every two months.
Your cancer may get better, get worse, or stay the same. Your health will be closely monitored during the study. Participation may help people in the future by increasing our understanding of the investigational or study medicine and ovarian cancer.
If your health gets worse, your study team and your study doctor will help you decide what to do, which may mean stopping your participation in the study. Potential risks from taking part in the study may include: side effects from taking the study medicine, for example diarrhea, nausea, fatigue; risks or discomforts from study procedures such as blood tests and body scans; risk of allergic reaction to the study medicine.
